NEUROCRINE BIOSCIENCES INC

11 February, 2025

Neurocrine Biosciences Reports Mixed Q4 Earnings and Faces Analyst Skepticism on Ingrezza Sales Outlook

Neurocrine Biosciences, a mid-cap biopharmaceutical company based in San Diego, California, recently held its fourth-quarter earnings conference call on February 6, 2025. The company, known for its fo...
Read More

10 February, 2025

Neurocrine Biosciences to Discuss Q4 2024 Earnings and Ongoing Commitment to Neurological Treatments in Upcoming Conference Call

Neurocrine Biosciences Inc. is poised to discuss its financial progress and future outlook during a conference call held on February 6, 2025, at 4:30 PM ET. This event will cover its fourth quarter an...
Read More

09 February, 2025

Neurocrine Biosciences to Discuss Q4 2024 Earnings and Ongoing Commitment to Neurological Treatments in Upcoming Conference Call

Neurocrine Biosciences Inc. is poised to discuss its financial progress and future outlook during a conference call held on February 6, 2025, at 4:30 PM ET. This event will cover its fourth quarter an...
Read More

08 February, 2025

Neurocrine Biosciences Projects Strong Fourth-Quarter Earnings Amidst Biotech Sector Growth and Competitive Pressures

Neurocrine Biosciences (NBIX) is generating significant attention as it reports its fourth-quarter earnings. Analysts project an adjusted earnings per share of $1.93, reflecting a robust 25% year-over...
Read More